ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years
Xuhui Tong
Matched on OpenAlex author ID A5010647321. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 13
2024: 2 papers · 2025: 2 papers
Papers 4
- TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic lethality. Co-author DOI 10.1136/gutjnl-2024-332782↗
- The TMBIM1-YBX1 axis orchestrates MDSC recruitment and immunosuppressive microenvironment in pancreatic cancer. Co-author DOI 10.7150/thno.111180↗
- Targeting CA9 restricts pancreatic cancer progression through pH regulation and ROS production. First author DOI 10.1007/s13402-024-01022-9↗
- NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced autophagy. Co-author DOI 10.1038/s41419-024-06984-0↗
Closest collaborators
The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Si Shi · 4 shared papers, 2024–2025 · strength 0.96
- Paper The TMBIM1-YBX1 axis orchestrates MDSC recruitment and immunosuppressive microenvironment in pancreatic cancer. DOI 10.7150/thno.111180↗
- Paper Targeting CA9 restricts pancreatic cancer progression through pH regulation and ROS production. DOI 10.1007/s13402-024-01022-9↗
- Paper NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced auto… DOI 10.1038/s41419-024-06984-0↗
- Mingming Xiao · 3 shared papers, 2024–2025 · strength 0.70
- Paper The TMBIM1-YBX1 axis orchestrates MDSC recruitment and immunosuppressive microenvironment in pancreatic cancer. DOI 10.7150/thno.111180↗
- Paper NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced auto… DOI 10.1038/s41419-024-06984-0↗
- Paper TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic leth… DOI 10.1136/gutjnl-2024-332782↗
- Xianjun Yu · 2 shared papers, 2024–2025 · strength 0.49
- Paper The TMBIM1-YBX1 axis orchestrates MDSC recruitment and immunosuppressive microenvironment in pancreatic cancer. DOI 10.7150/thno.111180↗
- Paper NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced auto… DOI 10.1038/s41419-024-06984-0↗
- H. J. Yang · 2 shared papers, 2024 · strength 0.47
- Jin Xu · 2 shared papers, 2024–2025 · strength 0.47
- Xianjun Yu · 2 shared papers, 2024–2025 · strength 0.47
- Yalan Lei · 2 shared papers, 2024–2025 · strength 0.42
- Paper NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced auto… DOI 10.1038/s41419-024-06984-0↗
- Paper TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic leth… DOI 10.1136/gutjnl-2024-332782↗
- Jing Yang · 1 shared paper, 2025 · strength 0.28
- Wei Wang · 1 shared paper, 2025 · strength 0.28
- Wei J. Wang · 1 shared paper, 2024 · strength 0.26
- Xiaoqi Mao · 1 shared paper, 2024 · strength 0.21
- Mingwei Dong · 1 shared paper, 2024 · strength 0.21
- Zhilong Ma · 1 shared paper, 2025 · strength 0.21
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.